Economic evaluation alongside the PAOLA-1 /ENGOT-ov25 trial: cost of ovarian cancer and cost-effectiveness of olaparib plus bevacizumab first-line maintenance

Authors: Lionel Perrier, Kevin Zarca, Thomas Cadet et al.
Publication: Cost Effectiveness and Resource Allocation
Published: Aug 6, 2026
Source: Crossref
Back to Search View Original Cite This Article

Related Articles

Comparing the Performance Evaluation Models of Gas Refineries Using AHP and TOPSIS

Mahmoud Mohammadi, Saber Ghasemi et al. - Oct 2121

Read More
Are the mosquito and vector control programs economic effective?

Lambros Tsourgiannis, Despoina Chatzipanagiotou - Jan 2117

Read More
Religion in the context of economic crisis: The generation’s z perspective

Aikaterini Stavrianea, Irene Kamenidou - Dec 2116

Read More
Consumers’ Buying Behaviour Towards Local Food in Greece During Economic Depression Period

Lambros Tsourgiannis, Efstratios Loizou et al. - Jan 2116

Read More
Evaluation of the potential of innovative enterprises in the region of Malopolska

Leszek Koziol, Radoslaw Pyrek et al. - Apr 2115

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0